What is KALYDECO™ and what does it treat?

KALYDECO™ (ivacaftor) is a newly approved drug by the FDA that treats cystic fibrosis in a specific patient group. It works by targeting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Which patients are eligible for KALYDECO™ treatment?

KALYDECO™ is approved for patients aged 6 and older who have at least one copy of the G551D mutation in their CFTR gene. This is a targeted therapy for a specific genetic subtype of cystic fibrosis.

What is the price of KALYDECO™?

Vertex Pharmaceuticals has established a wholesale acquisition price of $24,500 for a 30-day supply of KALYDECO™ in the United States. On an annualized basis, this amounts to $294,000.

What is the significance of this FDA approval for Vertex Pharmaceuticals?

This approval is highly significant as it marks the introduction of a novel, targeted therapy for cystic fibrosis. It demonstrates Vertex's capability in developing precision medicines for genetic diseases and opens up a new revenue stream for the company.

VRTX 8-K SEC Disclosure

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced a significant development on January 31, 2012, with the U.S. Food and Drug Administration's approval of KALYDECO™ (ivacaftor). This approval is for a specific patient population with cystic fibrosis: those aged 6 and older who possess at least one copy of the G551D mutation in the CFTR gene. This marks a crucial milestone for the company, introducing a targeted therapy for a genetic disorder.

Key Highlights

1FDA approval of KALYDECO™ (ivacaftor) for cystic fibrosis patients with the G551D mutation.
2KALYDECO™ is indicated for patients aged 6 and older with at least one copy of the G551D CFTR gene mutation.
3The wholesale acquisition price for KALYDECO™ is set at $24,500 for a 30-day supply in the U.S.
4This translates to an annual cost of $294,000 for a 30-day supply.
5The approval represents a significant advancement in targeted therapy for cystic fibrosis.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jan 31, 2012)

Summary

Key Highlights

Frequently Asked Questions